Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of free fatty acid suppression on myocardial and hepatic lipids in type 2 diabetes
2013-002656-32Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of acipimox in type 2 diabetes mellitus (T2DM), sponsored by Medical University of Vienna. Primary endpoint: Change in myocardial lipids/ejection fraction after FFA-suppression. Started Jul 2013; status: completed.
02
Drugs
acipimox
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-002656-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002656-32.